| Total patients | p Value | TROP2 overexpression | p Value | |||
| No | Yes | |||||
| n | DFS | OS | n (%) | n (%) | ||
| Intestinal-type carcinoma | ||||||
| Sex | ||||||
| Male | 63 | 0.60 | 0.53 | 23 (26) | 40 (45) | 0.32 |
| Female | 25 | 12 (14) | 13 (15) | |||
| Histological grade | ||||||
| Well | 3 | 0.51 | 0.06 | 2 (2) | 1 (1) | 0.48 |
| Moderate | 32 | 14 (16) | 18 (20) | |||
| Poor | 53 | 19 (22) | 34 (39) | |||
| Depth of wall invasion (T stage) | ||||||
| pT1 | 16 | 0.001 | 0.01 | 6 (7) | 10 (11) | 0.95 |
| pT2 | 52 | 20 (23) | 32 (36) | |||
| pT3 | 18 | 8 (9) | 10 (11) | |||
| pT4 | 2 | 1 (1) | 1 (1) | |||
| Lymph node metastasis | ||||||
| No | 36 | 0.001 | 0.01 | 12 (14) | 24 (27) | 0.30 |
| Yes | 52 | 23 (26) | 29 (33) | |||
| Distant metastasis | ||||||
| No | 79 | 0.003 | 0.001 | 33 (38) | 46 (52) | 0.25 |
| Yes | 9 | 2 (2) | 7 (8) | |||
| Resection margin | ||||||
| R0 vs. | 85 | 0.001 | 0.03 | 35 (41) | 50 (59) | 0.15 |
| R1+R2 | 3 | 3 (100) | ||||
| Stage (UICC) | ||||||
| I | 32 | 0.01 | 0.40 | 11 (13) | 21 (24) | 0.43 |
| II+III+IV | 56 | 24 (27) | 32 (36) | |||
| Diffuse-type carcinoma | ||||||
| Sex | ||||||
| Male | 7 | 0.48 | 0.81 | 4 (25) | 3 (19) | 0.37 |
| Female | 9 | 7 (44) | 2 (12) | |||
| Histological grade | ||||||
| Well | 1 | 0.13 | 0.15 | 1 (6) | 5 (31) | 0.48 |
| Moderate | 15 | 10 (63) | ||||
| Poor | ||||||
| Depth of wall invasion (T stage) | ||||||
| pT1 | 0.001 | 0.13 | 0.01 | |||
| pT2 | 8 | 8 (50) | ||||
| pT3 | 7 | 2 (12) | 5 (31) | |||
| pT4 | 1 | 1 (6) | ||||
| Lymph node metastasis | ||||||
| No | 10 | 0.79 | 0.61 | 8 (50) | 2 (12) | 0.21 |
| Yes | 6 | 3 (19) | 3 (19) | |||
| Distant metastasis | ||||||
| No | 15 | 0.001 | 0.05 | 10 (63) | 5 (31) | 0.48 |
| Yes | 1 | 1 (6) | ||||
| Resection margin | ||||||
| R0 vs. | 12 | 0.68 | 0.85 | 9 | 3 | 0.35 |
| R1+R2 | 4 | 2 | 2 | |||
| Stage (UICC) | NF | NF | ||||
| I | 5 | 5 (31) | 5 (31) | 0.06 | ||
| II+III+IV | 11 | 6 (38) | ||||
DFS, disease-free survival; OS, overall survival; NF, not feasible.